Newsfeeds - Spark Newswire

1 minute read

Morgan Stanley Initiates Coverage On Alpine Immune Sciences with Overweight Rating, Announces Price Target of $17

Today, 8:27 PM

Morgan Stanley analyst Michael Ulz initiates coverage on Alpine Immune Sciences (NASDAQ:ALPN) with a Overweight rating and announces Price Target of $17.

ALPN

1 minute read

SVB Leerink Initiates Coverage On Alpine Immune Sciences with Outperform Rating, Announces Price Target of $16

By Benzinga Newsdesk

Today, 8:27 PM

SVB Leerink analyst Thomas Smith initiates coverage on Alpine Immune Sciences (NASDAQ:ALPN) with a Outperform rating and announces Price Target of $16.

ALPN

1 minute read

Alpine Immune Sciences Q3 EPS $(0.42) Up From $(0.55) YoY, Sales $8.37M Down From $8.52M YoY

By Benzinga Newsdesk

Today, 8:27 PM

Alpine Immune Sciences (NASDAQ:ALPN) reported quarterly losses of $(0.42) per share. This is a 23.64 percent increase over losses of $(0.55) per share from the same period last year. The company reported $8.37 million

ALPN

17 minute read

Earnings

Earnings Scheduled For November 14, 2022

By Benzinga Insights

Today, 8:27 PM

Companies Reporting Before The Bell • Opiant Pharma (NASDAQ:OPNT) is estimated to report quarterly loss at $1.49 per share on revenue of $3.68 million.

AAIC

2 minute read

Alpine Immune Sciences Presents Update Of ALPN-303 Phase 1 (RUBY-1) Clinical Data At The American Society Of Nephrology Kidney Week 2022 Meeting

By Benzinga Newsdesk

Today, 8:27 PM

Alpine Immune Sciences, Inc. (NASDAQ:ALPN), a leading clinical-stage immunotherapy company focused on developing innovative treatments for autoimmune and inflammatory diseases, today presented a poster at the American

ALPN

23 minute read

News
Options

Stocks That Hit 52-Week Lows On Monday

By Benzinga Insights

Today, 8:27 PM

On Monday, 413 companies reached new 52-week lows.

AAN

1 minute read

Alpine Immune Sciences Stops Davoceticept Trials In Cancer Indications After Second Patient Death

By Vandana Singh

Today, 8:27 PM

Alpine Immune Sciences Inc (NASDAQ:ALPN) has voluntarily terminated enrollment in both clinical studies involving davoceticept (ALPN-202), an investigational CD28 costimulator, and…

ABBV